Rizatriptan Benzoate Tablet
Product Images NDC 67877-261

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 67877-261). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rizatriptan 10mg 100

Label for Rizatriptan Benzoate Tablets, USP 10 mg, oral tablets. The label indicates a package of 100 tablets, distributed by Ascend Laboratories, LLC, Parsippany, NJ, and manufactured by Alkem Laboratories Ltd., Mumbai, India. The label includes storage instructions and a barcode.*

FDA Label Image

Rizatriptan 10mg 18

Packaging label for Rizatriptan Benzoate Tablets, USP 10 mg oral unit-dose tablets. The label shows the brand Ascend Laboratories, LLC, with NDC 67877-262-18. The package contains 18 unit-dose tablets, arranged as 3 x 6. The label notes the package is not child resistant and includes storage instructions as well as manufacturer and distributor details.*

FDA Label Image

Rizatriptan 5mg 12

Rizatriptan Benzoate Tablets, USP 5 mg unit-dose package carton from Ascend Laboratories, LLC. The package contains 12 tablets (2 strips of 6 unit dose tablets) and is labeled Rx Only. It includes storage instructions and manufacturer information by Alkem Laboratories Ltd., India.*

FDA Label Image

Rizatriptan 5mg 30

Label for Rizatriptan Benzoate Tablets, USP 5 mg by Ascend Laboratories, LLC. The oral tablet label indicates 30 tablets per package and specifies each tablet contains 7.265 mg of rizatriptan benzoate USP, equivalent to 5 mg rizatriptan. It includes storage instructions and manufacturer and distributor information, with an NDC 67877-261-30 and a barcode.*

FDA Label Image

Rizatriptan Fig 1

A line graph showing the estimated probability of response over hours post-dose for Rizatriptan Benzoate 5 mg, 10 mg, and placebo. The x-axis represents hours post-dose (0 to 2), and the y-axis represents the estimated probability of response (0% to 100%). Rizatriptan Benzoate 10 mg shows the highest probability increase, followed by 5 mg and placebo.*

FDA Label Image

Rizatriptan Fig 2

A line graph showing the estimated probability of medication or rescue over 24 hours post-dose. It compares placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg, with probability increasing over time for each treatment, showing higher probabilities for active doses than placebo.*

FDA Label Image

Rizatriptan Fig 5

A line graph comparing the percent response with 95% confidence intervals of Rizatriptan Benzoate versus placebo over time in hours post stage 2 dose. The x-axis represents hours post stage 2 dose from 0.5 to 2.0, and the y-axis represents the percent response from 0% to 100%. Two lines show increasing percent response over time, with Rizatriptan Benzoate consistently higher than placebo.*

FDA Label Image

Rizatriptan Structure

Chemical structure of Rizatriptan Benzoate showing the detailed arrangement of its molecular components, including the indole ring system linked to a methylated amine and a benzoic acid group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.